Advaxis Chairman/CEO Thomas A. Moore to Present at the World Vaccine Congress 2010
Westfields Marriott Washington Dulles, Chantilly, VA
April 21, 2010, 4:30 PM EDT and April 22, 2010, 12:40 PM EDT
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Apr 20, 2010 - Chairman/CEO Thomas A. Moore of Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, will be a panelist at the World Vaccine Congress 2010 tomorrow, Wednesday, April 21, 2010 at 4:30 PM EDT and Thursday, April 22, 2010 at 12:40 PM EDT.
The first panel session on Wednesday will address: “What real potential exists for vaccine antigen delivery technologies for future vaccine development?”
The second panel session on Thursday will address: “What lessons are being learned from late stage clinical studies?”
About World Vaccine Congress
Now in its 10th year, World Vaccine Congress 2010 remains the industry's definitive vaccine industry event for major vaccine players and their respective senior level representatives. Officially, the longest-running and largest vaccine industry event in North America, World Vaccine Congress continues to deliver a forum where the ever-changing dynamics of an industry in resurgence are discussed and acted upon by the industry's most senior figures. For more information on the list of presenting companies, please visit: http://www.terrapinn.com/2010/wvcdc/
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) immunotherapeutics that deliver engineered tumor antigens, which stimulate multiple, simultaneous, immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research – UK. The Company's technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis' scientific advisory board. Please visit the Company's portals: advaxis.com | facebook | twitter | LinkedIn
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Contact: Advaxis, Incorporated
Conrad F. Mir, 732-545-1590
Diana Moore, 732-545-1590
Posted: April 2010